✦ LIBER ✦

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ Scribed by McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak, Erhan; Song, James X.; Cox, David; Vahdat, Linda T.

Book ID: 125356854
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 127 KB
Volume: 146
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-014-3010-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of eribulin mesylate as fi

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 405 KB

Phase 2, Multicenter, Single-Arm Study o

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

✍ Wilks, Sharon; Puhalla, Shannon; O'Shaughnessy, Joyce; Schwartzberg, Lee; Berrak 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 169 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Brufsky, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 99 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB

Phase II Study of Gemcitabine and Bevaci

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Rachel Borson; Graydon Harker; James Reeves; Thaddeus Beck; Steven Hager; Willia 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 387 KB

Phase IIa Trial of Trastuzumab Emtansine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer

✍ Miller, K. D.; Dieras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; A 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB